Key Highlights

  • MoonLake's Phase 3 IZAR-1 trial of sonelokimab achieved all Week 16 clinical endpoints.
  • 42.1% of patients reached ACR50.
  • 61% achieved PASI90.
  • The company's $537 million cash position provides a runway into mid-2028.

MoonLake Immunotherapeutics ( Nasdaq : MLTX) announced that its Phase 3 IZAR-1 trial of sonelokimab in biologic-naive psoriatic arthritis patients achieved all Week 16 clinical endpoints.

What Happened

The trial showed 42.1% of patients reaching ACR50 and 61% achieving PASI90, while maintaining a safety profile consistent with prior data.

ACR50 and PASI90 are widely used composite measures of joint and skin symptom improvement in psoriatic arthritis and psoriasis, and achieving all Week 16 endpoints simultaneously represents a comprehensive positive result across both the joint and skin manifestations of the disease.

Market Reaction

The disclosed information does not include stock price or trading data for MoonLake Immunotherapeutics following the Phase 3 results.

Achieving every prespecified endpoint at this stage of a pivotal trial is generally viewed as a strong signal supporting a future regulatory filing, subject to confirmation from the primary readout still to come.

Outlook

The company's $537 million cash position provides a runway into mid-2028 as it awaits the primary readout for the trial, expected in the first half of 2027.

The extended cash runway relative to the primary readout timeline gives MoonLake flexibility to pursue additional indications for sonelokimab without an immediate need to raise Capital , a structural advantage as the company awaits its next major data milestone.